The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer
Abstract
EGFR inhibitor erlotinib synergizes with anti–PD-1 in a mouse model of lung adenocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Gunn, M. D., Kyuwa, S., Tam, C., Kakiuchi, T., Matsuzawa, A., Williams, L. T., & Nakano, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.3.451 · Cited by 1,019
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Self-citationCheckpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839
Integrated molecular analysis of adult T cell leukemia/lymphoma
Kataoka, K., Nagata, Y., Kitanaka, A., Shiraishi, Y., Shimamura, T., Yasunaga, J.-I., Totoki, Y., Chiba, K., Sato-Otsubo, A., Nagae, G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3415 · Cited by 794
Self-citationTran, D. Q., Ramsey, H., & Shevach, E. M. (2007) · Blood · doi:10.1182/blood-2007-06-094656 · Cited by 743
Chen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000500 · Cited by 669
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 645
Mitsudomi, T., & Yatabe, Y. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00607.x · Cited by 606
CCR4 and its ligands: from bench to bedside
Yoshie, O., & Matsushima, K. (2015) · International Immunology · doi:10.1093/intimm/dxu079 · Cited by 427
Zaiss, D. M. W., van Loosdregt, J., Gorlani, A., Bekker, C. P. J., Gröne, A., Sibilia, M., van Bergen en Henegouwen, P. M. P., Roovers, R. C., Coffer, P. J., & Sijts, A. J. A. M. (2013) · Immunity · doi:10.1016/j.immuni.2012.09.023 · Cited by 418
Control of the Immune Response by Pro-Angiogenic Factors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00070 · Cited by 325
CXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
Liang, D., Huang, X., Guan-Jun, D., Hu, E., Sheng, C., Wang, T., Hu, Q., Ni, Y., & Ya-yi, H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.08.011 · Cited by 161
Chemokines, selectins and intracellular calcium flux: temporal and spatial cues for leukocyte arrest
Dixit, N., & Simon, S. I. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00188 · Cited by 133
The UL144 gene product of human cytomegalovirus activates NFκB via a TRAF6‐dependent mechanism
Poole, E. L., King, C. A., Sinclair, J. H., & Alcamí, A. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601287 · Cited by 109
Takeuchi, Y., Tanemura, A., Tada, Y., Katayama, I., Kumanogoh, A., & Nishikawa, H. (2017) · International Immunology · doi:10.1093/intimm/dxx073 · Cited by 88
Self-citationRegulatory T Cells: Molecular and Cellular Basis for Immunoregulation
Togashi, Y., & Nishikawa, H. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_58 · Cited by 86
Self-citationNakamura, N., Chin, H., Miyasaka, N., & Miura, O. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19483 · Cited by 82
Development of Lung Adenocarcinomas with Exclusive Dependence on Oncogene Fusions
Saito, M., Shimada, Y., Shiraishi, K., Sakamoto, H., Tsuta, K., Totsuka, H., Chiku, S., Ichikawa, H., Kato, M., WATANABE, S.-I. I., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3282 · Cited by 44
The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment
Macdonald, F., & Zaiss, D. M. W. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00575 · Cited by 41
Matsuzaki, S., Ishizuka, T., Hisada, T., Aoki, H., Komachi, M., Ichimonji, I., Utsugi, M., Ono, A., Koga, Y., Dobashi, K., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000904 · Cited by 25
Tseng, P., Chen, C., Shan, Y., & Lin, C. (2016) · Oncotarget · doi:10.18632/oncotarget.7750 · Cited by 21
Cited by
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.001 · Cited by 892
Self-citationRegulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Vitaly, K., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 783
Self-citationTumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
Metadata
- Authors
- Sugiyama, E., Togashi, Y., Takeuchi, Y., Shinya, S., Tada, Y., Kataoka, K., Tane, K., Sato, E., Ishii, G., Goto, K., Shintani, Y., Okumura, M., Tsuboi, M., & Nishikawa, H.
- Venue
- Science Immunology
- Published
- 2020-01-03
- Volume
- 5
- Issue
- 43
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W3003320500
- Cited by
- 289
- References
- 38
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.